Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy
NCT06185205Phase 2Recruiting
- Sponsor
- Virginia Commonwealth University
- Start
- Dec 2023
- Primary completion
- Jan 2031
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in breast cancer, sponsored by Virginia Commonwealth University. Primary endpoint: Toxicity of APBI treatment course at 3 years. Started Dec 2023; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06185205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06185205.